AI Terminal
Theradiag
Report Publication Announcement • Jan 6, 2023
1702_iss_2023-01-06_dafb4223-c85d-4e89-a500-367b204f794a.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
THERADIAG announces its 2023 financial calendar
Croissy-Beaubourg, January 6, 2023, 7.30 am CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and theranostics, today announces its schedule for the publication of financial information for 2023.
| Events | Dates* |
|---|---|
| 2022 Full-Year Annual Revenue | Monday January 16, 2023 |
| 2022 Full-Year Results | Monday April 3, 2023 |
| 2023 First-Quarter Revenue | Monday 17 April, 2023 |
| Annual General Meeting | Tuesday May 16, 2023 |
| 2023 First-Half Revenue | Monday July 17, 2023 |
| 2023 First-Half Results | Monday September 18, 2023 |
| 2023 Third-Quarter Revenue | Wednesday October 11, 2023 |
(*) Subject to modifications. Press releases will be published before market open.
About Theradiag
Theradiag is the market leader in biotherapy monitoring. Capitalizing on its expertise in the diagnostics market, the Company has been developing, manufacturing and marketing innovative in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered "theranostics" testing (combining therapy with diagnosis), which measures the efficacy of biotherapy in the treatment of chronic inflammatory diseases. Going beyond mere diagnosis, Theranostics aims to help clinicians set up "customized treatment" for each patient. This method favors the individualization of treatment, evaluation of its efficacy and the prevention of drug resistance. In response to this challenge, Theradiag develops and markets the CE-marked TRACKER® range, a comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has operations in over 70 countries and employs over 60 people. In 2021, the Company posted revenue of €11.1 million. The Theradiag share is listed on Euronext Growth Paris (ISIN: FR0004197747) and is eligible for the French PEA-PME personal equity plan. For more information about Theradiag, please visit our website: https://www.theradiag.com/
Theradiag Bertrand de Castelnau CEO/Managing Director Tel.: +33 (0)1 64 62 10 12 [email protected]
NewCap
Financial Communications & Investor Relations Pierre Laurent Quentin Massé Tel.: +33 (0)1 44 71 94 94 [email protected]
NewCap Media Relations Arthur Rouillé Tél. : +33 (0)1 44 71 94 94 [email protected]r